Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 17442-17444 [2015-07423]

Download as PDF 17442 Federal Register / Vol. 80, No. 62 / Wednesday, April 1, 2015 / Notices competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NIA. Date: May 19, 2015. Time: 8:00 a.m. to 8:30 a.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institute on Aging, Biomedical Research Center, 3rd Floor Conference Room, 251 Bayview Boulevard, Baltimore, MD 21224. Open: 8:30 a.m. to 11:45 a.m. Agenda: Committee discussion, individual presentations, laboratory overview. Place: National Institute on Aging, Biomedical Research Center, 3rd Floor Conference Room, 251 Bayview Boulevard, Baltimore, MD 21224. Closed: 11:45 a.m. to 12:45 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institute on Aging, Biomedical Research Center, 3rd Floor Conference Room, 251 Bayview Boulevard, Baltimore, MD 21224. Open: 12:45 p.m. to 3:00 p.m. Agenda: Committee discussion, individual presentations, laboratory overview. Place: National Institute on Aging, Biomedical Research Center, 3rd Floor Conference Room, 251 Bayview Boulevard, Baltimore, MD 21224. Closed: 3:00 p.m. to 4:00 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institute on Aging, Biomedical Research Center, 3rd Floor Conference Room, 251 Bayview Boulevard, Baltimore, MD 21224. Contact Person: Luigi Ferrucci, Ph.D., MD, Scientific Director, National Institute on Aging, 251 Bayview Boulevard, Suite 100, Room 4C225, Baltimore, MD 21224, 410– 558–8110, LF27Z@NIH.GOV. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: March 26, 2015. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES mstockstill on DSK4VPTVN1PROD with NOTICES Dated: March 26, 2015. Carolyn Baum, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–07342 Filed 3–31–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board Jkt 235001 (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS). AGENCY: National Institutes of Health 18:37 Mar 31, 2015 Name of Committee: Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke. Date: May 17–19, 2015. Time: 7:00 p.m. to 10:30 a.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Alan P. Koretsky, Ph.D., Scientific Director, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, NIH, 35 Convent Drive, Room 6A908, Bethesda, MD 20892, (301) 435–2232, koretskya@ninds.nih.gov. Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies [FR Doc. 2015–07337 Filed 3–31–15; 8:45 am] VerDate Sep<11>2014 of Scientific Counselors, National Advisory Neurological Disorders and Stroke. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Neurological Disorders and Stroke, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing SUMMARY: PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809). A notice listing all currently HHScertified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at https://beta.samhsa.gov/ workplace. FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 7– 1051, One Choke Cherry Road, Rockville, Maryland 20857; 240–276– 2600 (voice), 240–276–2610 (fax). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. The ‘‘Mandatory Guidelines for Federal Workplace Drug Testing Programs,’’ as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies. To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards. In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS- E:\FR\FM\01APN1.SGM 01APN1 mstockstill on DSK4VPTVN1PROD with NOTICES Federal Register / Vol. 80, No. 62 / Wednesday, April 1, 2015 / Notices certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens: HHS-Certified Instrumented Initial Testing Facilities: Gamma-Dynacare Medical Laboratories 6628 50th Street NW. Edmonton, AB Canada T6B 2N7 780–784–1190 HHS-Certified Laboratories: ACM Medical Laboratory, Inc. 160 Elmgrove Park Rochester, NY 14624 585–429–2264 Aegis Analytical Laboratories, Inc. 345 Hill Ave. Nashville, TN 37210 615–255–2400 (Formerly: Aegis Sciences Corporation, Aegis Analytical Laboratories, Inc., Aegis Analytical Laboratories) Alere Toxicology Services 1111 Newton St. Gretna, LA 70053 504–361–8989/800–433–3823 (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.) Alere Toxicology Services 450 Southlake Blvd. Richmond, VA 23236 804–378–9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.) Baptist Medical Center-Toxicology Laboratory 11401 I–30 Little Rock, AR 72209–7056 501–202–2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center) Clinical Reference Lab 8433 Quivira Road Lenexa, KS 66215–2802 800–445–6917 DrugScan, Inc. 200 Precision Road, Suite 200 Horsham, PA 19044 800–235–4890 ElSohly Laboratories, Inc. 5 Industrial Park Drive Oxford, MS 38655 662–236–2609 Fortes Laboratories, Inc. 25749 SW Canyon Creek Road, Suite 600 Wilsonville, OR 97070 503–486–1023 Gamma-Dynacare Medical Laboratories* A Division of the Gamma-Dynacare Laboratory Partnership VerDate Sep<11>2014 18:37 Mar 31, 2015 Jkt 235001 245 Pall Mall Street London, ONT, Canada N6A 1P4 519–679–1630 Laboratory Corporation of America Holdings 7207 N. Gessner Road Houston, TX 77040 713–856–8288/800–800–2387 Laboratory Corporation of America Holdings 69 First Ave. Raritan, NJ 08869 908–526–2400/800–437–4986 (Formerly: Roche Biomedical Laboratories, Inc.) Laboratory Corporation of America Holdings 1904 Alexander Drive Research Triangle Park, NC 27709 919–572–6900/800–833–3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group) Laboratory Corporation of America Holdings 1120 Main Street Southaven, MS 38671 866–827–8042/800–233–6339 (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/ National Laboratory Center) LabOne, Inc. d/b/a Quest Diagnostics 10101 Renner Blvd. Lenexa, KS 66219 913–888–3927/800–873–8845 (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.) MedTox Laboratories, Inc. 402 W. County Road D St. Paul, MN 55112 651–636–7466/800–832–3244 MetroLab-Legacy Laboratory Services 1225 NE 2nd Ave. Portland, OR 97232 503–413–5295/800–950–5295 Minneapolis Veterans Affairs Medical Center Forensic Toxicology Laboratory 1 Veterans Drive Minneapolis, MN 55417 612–725–2088 National Toxicology Laboratories, Inc. 1100 California Ave. Bakersfield, CA 93304 661–322–4250/800–350–3515 One Source Toxicology Laboratory, Inc. 1213 Genoa-Red Bluff Pasadena, TX 77504 888–747–3774 (Formerly: University of Texas PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 17443 Medical Branch, Clinical Chemistry Division; UTMB PathologyToxicology Laboratory) Pacific Toxicology Laboratories 9348 DeSoto Ave. Chatsworth, CA 91311 800–328–6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory) Pathology Associates Medical Laboratories 110 West Cliff Dr. Spokane, WA 99204 509–755–8991/800–541–7891x7 Phamatech, Inc. 15175 Innovation Drive San Diego, CA 92128 888–635–5840 Quest Diagnostics Incorporated 1777 Montreal Circle Tucker, GA 30084 800–729–6432 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories) Quest Diagnostics Incorporated 400 Egypt Road Norristown, PA 19403 610–631–4600/877–642–2216 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories) Quest Diagnostics Incorporated 8401 Fallbrook Ave. West Hills, CA 91304 818–737–6370 (Formerly: SmithKline Beecham Clinical Laboratories) Redwood Toxicology Laboratory 3700650 Westwind Blvd. Santa Rosa, CA 95403 800–255–2159 Southwest Laboratories 4625 E. Cotton Center Boulevard Suite 177 Phoenix, AZ 85040 602–438–8507/800–279–0027 STERLING Reference Laboratories 2617 East L Street Tacoma, Washington 98421 800–442–0438 U.S. Army Forensic Toxicology Drug Testing Laboratory 2490 Wilson St. Fort George G. Meade, MD 20755– 5235 301–677–7085 * The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the E:\FR\FM\01APN1.SGM 01APN1 17444 Federal Register / Vol. 80, No. 62 / Wednesday, April 1, 2015 / Notices certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHScertified laboratories and participate in the NLCP certification maintenance program. Janine Denis Cook, Chemist Division of Workplace Programs, Center for Substance Abuse Prevention, SAMHSA. [FR Doc. 2015–07423 Filed 3–31–15; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Toxic Substances and Disease Registry [Docket No. ATSDR–2015–0001] Proposed Substances To Be Evaluated for Set 29 Toxicological Profiles Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS). ACTION: Request for comments on the proposed substances to be evaluated for Set 29 toxicological profiles. AGENCY: ATSDR is initiating the development of its 29th set of toxicological profiles (CERCLA Set 29). This notice announces the list of proposed substances that will be evaluated for CERCLA Set 29 toxicological profile development. ATSDR’s Division of Toxicology and Human Health Sciences is soliciting public nominations from the list of proposed substances to be evaluated for toxicological profile development. ATSDR also will consider the nomination of any additional, nonCERCLA substances that may have public health implications, on the basis mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:37 Mar 31, 2015 Jkt 235001 of ATSDR’s authority to prepare toxicological profiles for substances not found at sites on the National Priorities List. The agency will do so in order to ‘‘. . . establish and maintain inventory of literature, research, and studies on the health effects of toxic substances’’ under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and to support the site-specific response actions conducted by ATSDR, as otherwise necessary. DATES: Nominations from the Substance Priority List and/or additional substances must be submitted within 30 days of the publication of this notice. ADDRESSES: You may submit nominations, identified by Docket No. ATSDR–2015–0001, by any of the following methods: *Internet: Access the Federal eRulemaking portal at https:// www.regulations.gov. Follow the instructions for submitting comments. *Mail: Division of Toxicology and Human Health Sciences, 1600 Clifton Rd. NE., MS F–57, Atlanta, Ga., 30333. Instructions: All submissions must include the agency name and docket number for this notice. All relevant comments will be posted without change. This means that no confidential business information or other confidential information should be submitted in response to this notice. Refer to the section Submission of Nominations (below) for the specific information required. FOR FURTHER INFORMATION CONTACT: For further information, please contact Commander Jessilynn B. Taylor, Division of Toxicology and Human Health Sciences, 1600 Clifton Rd. NE., MS F–57, Atlanta, Ga., 30333, Email: tpcandidatecomments@cdc.gov; phone: 1–800–232–4636. SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization Act of 1986 (SARA) [42 U.S.C. 9601 et seq.] amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund) [42 U.S.C. 9601 et seq.] by establishing certain requirements for ATSDR and the U.S. Environmental Protection Agency (EPA) with regard to hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL). Among these statutory requirements is a mandate for the Administrator of ATSDR to prepare toxicological profiles for each substance included on the Priority List of Hazardous Substances. This list identifies 275 hazardous substances that ATSDR and EPA have determined pose PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 the most significant current potential threat to human health. The availability of the revised list of the 275 priority substances was announced in the Federal Register on May 28, 2014 (79 FR 30613). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17,1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 56792); October 25, 2001 (66 FR 54014); November 7, 2003 (68 FR 63098); December 7, 2005 (70 FR 72840); and March 6, 2008 (73 FR 12178); November 3, 2011 (76 FR 68193). Substances To Be Evaluated for Set 29 Toxicological Profiles Each year, ATSDR develops a list of substances to be considered for toxicological profile development. The Set 29 nomination process includes consideration of all substances on ATSDR’s Priority List of Hazardous Substances, also known as the Substance Priority List (SPL), as well as other substances nominated by the public. The 275 substances on the SPL will be considered for Set 29 Toxicological Profile development. This list may be found at the following Web site: www.atsdr.cdc.gov/SPL. Submission of Nominations for the Evaluation of Set 29 Proposed Substances Today’s notice invites voluntary public nominations for substances included on the SPL and for substances not listed on the SPL. All nominations should include the full name of the nominator, affiliation, and email address. When nominating a non-SPL substance, please include the rationale for the nomination. Please note that email addresses will not be posted on regulations.gov. ATSDR will evaluate all data and information associated with nominated substances and will determine the final list of substances to be chosen for toxicological profile development. Substances will be chosen according to ATSDR’s specific guidelines for selection. These guidelines can be found in the Selection Criteria announced in the Federal Register on May 7, 1993 (58 FR 27286–27287). A hard copy of the Selection Criteria is available upon request or may be accessed at: https:// www.atsdr.cdc.gov/toxprofiles/ guidance/criteria_for_selecting_tp_ support.pdf. E:\FR\FM\01APN1.SGM 01APN1

Agencies

[Federal Register Volume 80, Number 62 (Wednesday, April 1, 2015)]
[Notices]
[Pages 17442-17444]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-07423]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of HHS-Certified Laboratories and Instrumented 
Initial Testing Facilities Which Meet Minimum Standards To Engage in 
Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (HHS) notifies 
federal agencies of the laboratories and Instrumented Initial Testing 
Facilities (IITF) currently certified to meet the standards of the 
Mandatory Guidelines for Federal Workplace Drug Testing Programs 
(Mandatory Guidelines). The Mandatory Guidelines were first published 
in the Federal Register on April 11, 1988 (53 FR 11970), and 
subsequently revised in the Federal Register on June 9, 1994 (59 FR 
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); 
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and 
on April 30, 2010 (75 FR 22809).
    A notice listing all currently HHS-certified laboratories and IITFs 
is published in the Federal Register during the first week of each 
month. If any laboratory or IITF certification is suspended or revoked, 
the laboratory or IITF will be omitted from subsequent lists until such 
time as it is restored to full certification under the Mandatory 
Guidelines.
    If any laboratory or IITF has withdrawn from the HHS National 
Laboratory Certification Program (NLCP) during the past month, it will 
be listed at the end and will be omitted from the monthly listing 
thereafter.
    This notice is also available on the Internet at https://beta.samhsa.gov/workplace.

FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace 
Programs, SAMHSA/CSAP, Room 7-1051, One Choke Cherry Road, Rockville, 
Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially 
developed in accordance with Executive Order 12564 and section 503 of 
Pub. L. 100-71. The ``Mandatory Guidelines for Federal Workplace Drug 
Testing Programs,'' as amended in the revisions listed above, requires 
strict standards that laboratories and IITFs must meet in order to 
conduct drug and specimen validity tests on urine specimens for federal 
agencies.
    To become certified, an applicant laboratory or IITF must undergo 
three rounds of performance testing plus an on-site inspection. To 
maintain that certification, a laboratory or IITF must participate in a 
quarterly performance testing program plus undergo periodic, on-site 
inspections.
    Laboratories and IITFs in the applicant stage of certification are 
not to be considered as meeting the minimum requirements described in 
the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must 
have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), 
which attests that it has met minimum standards.
    In accordance with the Mandatory Guidelines dated November 25, 2008 
(73 FR 71858), the following HHS-

[[Page 17443]]

certified laboratories and IITFs meet the minimum standards to conduct 
drug and specimen validity tests on urine specimens:

HHS-Certified Instrumented Initial Testing Facilities:
    Gamma-Dynacare Medical Laboratories
    6628 50th Street NW.
    Edmonton, AB Canada T6B 2N7
    780-784-1190

HHS-Certified Laboratories:
    ACM Medical Laboratory, Inc.
    160 Elmgrove Park
    Rochester, NY 14624
    585-429-2264

    Aegis Analytical Laboratories, Inc.
    345 Hill Ave.
    Nashville, TN 37210
    615-255-2400
    (Formerly: Aegis Sciences Corporation, Aegis Analytical 
Laboratories, Inc., Aegis Analytical Laboratories)

    Alere Toxicology Services
    1111 Newton St.
    Gretna, LA 70053
    504-361-8989/800-433-3823
    (Formerly: Kroll Laboratory Specialists, Inc., Laboratory 
Specialists, Inc.)

    Alere Toxicology Services
    450 Southlake Blvd.
    Richmond, VA 23236
    804-378-9130
    (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing 
Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.)

    Baptist Medical Center-Toxicology Laboratory
    11401 I-30
    Little Rock, AR 72209-7056
    501-202-2783
    (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)

    Clinical Reference Lab
    8433 Quivira Road
    Lenexa, KS 66215-2802
    800-445-6917
    DrugScan, Inc.
    200 Precision Road, Suite 200
    Horsham, PA 19044
    800-235-4890

    ElSohly Laboratories, Inc.
    5 Industrial Park Drive
    Oxford, MS 38655
    662-236-2609

    Fortes Laboratories, Inc.
    25749 SW Canyon Creek Road, Suite 600
    Wilsonville, OR 97070
    503-486-1023

    Gamma-Dynacare Medical Laboratories*
    A Division of the Gamma-Dynacare Laboratory Partnership
    245 Pall Mall Street
    London, ONT, Canada N6A 1P4
    519-679-1630

    Laboratory Corporation of America Holdings
    7207 N. Gessner Road
    Houston, TX 77040
    713-856-8288/800-800-2387

    Laboratory Corporation of America Holdings
    69 First Ave.
    Raritan, NJ 08869
    908-526-2400/800-437-4986
    (Formerly: Roche Biomedical Laboratories, Inc.)

    Laboratory Corporation of America Holdings
    1904 Alexander Drive
    Research Triangle Park, NC 27709
    919-572-6900/800-833-3984
    (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem 
Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche 
Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of 
the Roche Group)

    Laboratory Corporation of America Holdings
    1120 Main Street
    Southaven, MS 38671
    866-827-8042/800-233-6339
    (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/
National Laboratory Center)

    LabOne, Inc. d/b/a Quest Diagnostics
    10101 Renner Blvd.
    Lenexa, KS 66219
    913-888-3927/800-873-8845
    (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for 
Laboratory Services, a Division of LabOne, Inc.)

    MedTox Laboratories, Inc.
    402 W. County Road D
    St. Paul, MN 55112
    651-636-7466/800-832-3244

    MetroLab-Legacy Laboratory Services
    1225 NE 2nd Ave.
    Portland, OR 97232
    503-413-5295/800-950-5295

    Minneapolis Veterans Affairs Medical Center
    Forensic Toxicology Laboratory
    1 Veterans Drive
    Minneapolis, MN 55417
    612-725-2088

    National Toxicology Laboratories, Inc.
    1100 California Ave.
    Bakersfield, CA 93304
    661-322-4250/800-350-3515

    One Source Toxicology Laboratory, Inc.
    1213 Genoa-Red Bluff
    Pasadena, TX 77504
    888-747-3774
    (Formerly: University of Texas Medical Branch, Clinical Chemistry 
Division; UTMB Pathology-Toxicology Laboratory)

    Pacific Toxicology Laboratories
    9348 DeSoto Ave.
    Chatsworth, CA 91311
    800-328-6942
    (Formerly: Centinela Hospital Airport Toxicology Laboratory)

    Pathology Associates Medical Laboratories
    110 West Cliff Dr.
    Spokane, WA 99204
    509-755-8991/800-541-7891x7

    Phamatech, Inc.
    15175 Innovation Drive
    San Diego, CA 92128
    888-635-5840

    Quest Diagnostics Incorporated
    1777 Montreal Circle
    Tucker, GA 30084
    800-729-6432
    (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline 
Bio-Science Laboratories)

    Quest Diagnostics Incorporated
    400 Egypt Road
    Norristown, PA 19403
    610-631-4600/877-642-2216
    (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline 
Bio-Science Laboratories)

    Quest Diagnostics Incorporated
    8401 Fallbrook Ave.
    West Hills, CA 91304
    818-737-6370
    (Formerly: SmithKline Beecham Clinical Laboratories)

    Redwood Toxicology Laboratory
    3700650 Westwind Blvd.
    Santa Rosa, CA 95403
    800-255-2159

    Southwest Laboratories
    4625 E. Cotton Center Boulevard
    Suite 177
    Phoenix, AZ 85040
    602-438-8507/800-279-0027

    STERLING Reference Laboratories
    2617 East L Street
    Tacoma, Washington 98421
    800-442-0438

    U.S. Army Forensic Toxicology Drug Testing Laboratory
    2490 Wilson St.
    Fort George G. Meade, MD 20755-5235
    301-677-7085

    * The Standards Council of Canada (SCC) voted to end its Laboratory 
Accreditation Program for Substance Abuse (LAPSA) effective May 12, 
1998. Laboratories certified through that program were accredited to 
conduct forensic urine drug testing as required by U.S. Department of 
Transportation (DOT) regulations. As of that date, the

[[Page 17444]]

certification of those accredited Canadian laboratories will continue 
under DOT authority. The responsibility for conducting quarterly 
performance testing plus periodic on-site inspections of those LAPSA-
accredited laboratories was transferred to the U.S. HHS, with the HHS' 
NLCP contractor continuing to have an active role in the performance 
testing and laboratory inspection processes. Other Canadian 
laboratories wishing to be considered for the NLCP may apply directly 
to the NLCP contractor just as U.S. laboratories do.
    Upon finding a Canadian laboratory to be qualified, HHS will 
recommend that DOT certify the laboratory (Federal Register, July 16, 
1996) as meeting the minimum standards of the Mandatory Guidelines 
published in the Federal Register on April 30, 2010 (75 FR 22809). 
After receiving DOT certification, the laboratory will be included in 
the monthly list of HHS-certified laboratories and participate in the 
NLCP certification maintenance program.

Janine Denis Cook,
Chemist Division of Workplace Programs, Center for Substance Abuse 
Prevention, SAMHSA.
[FR Doc. 2015-07423 Filed 3-31-15; 8:45 am]
BILLING CODE 4162-20-P